Mainz Biomed (QUCY) Stock Price, News & Analysis

Company Overview

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

Key Stats

• Today's Range: $2.46 to $4.93
• 50-Day Range: $0.32 to $3.46
• 52-Week Range: $0.30 to $4.93
• Volume: 81.65 million shs
• Average Volume: 10.26 million shs
• Market Capitalization: $43.32 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Reduce

Mainz Biomed Stock Analysis - MarketRank™

Mainz Biomed scored higher than 10% of companies evaluated by MarketBeat, and ranked 74th out of 81 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Reduce

Consensus Rating

Mainz Biomed has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Mainz Biomed has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Mainz Biomed is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mainz Biomed is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Mainz Biomed has a P/B Ratio of 49.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.51% of the float of Mainz Biomed has been sold short.

Short Interest Ratio / Days to Cover

Mainz Biomed has a short interest ratio ("days to cover") of 0.68, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mainz Biomed has recently increased by 40.26%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mainz Biomed does not currently pay a dividend.

Dividend Growth

Mainz Biomed does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.21

News Sentiment

Mainz Biomed has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Manufacturing companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Mainz Biomed this week, compared to 2 articles on an average week.

Search Interest

8 people have searched for QUCY on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

5 people have added Mainz Biomed to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Mainz Biomed insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.80% of the stock of Mainz Biomed is held by insiders.

Percentage Held by Institutions

Mainz Biomed has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 3/31/2026
• Today: 5/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:QUCY
• CIK: 1874252
• Web: N/A
• Phone: 49 6131 5542860
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 1.55
• Current Ratio: 0.50
• Quick Ratio: 0.44

Sales & Book Value

• Annual Sales: $540 thousand
• Price / Sales: 80.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.07 per share
• Price / Book: 49.43

Miscellaneous

• Outstanding Shares: 12,520,000
• Free Float: 11,289,000
• Market Cap: $43.32 million
• Optionable: N/A
• Beta: 0.42